FDA Accepts Andrx’ Corrective Action Plan On Manufacturing Issues
This article was originally published in The Pink Sheet Daily
Executive Summary
Agency’s acceptance means that manufacturing deficiencies will not result in warning letter or consent decree, and will not hold up ANDA approvals, Andrx CEO Rice says.